Good afternoon Densy and thank you for starting this thread and bringing to the forefront many existing SH concerns.
I have had to deal with a significant event within my Family that is now 90% resolved.
My first entry back into the ASX was of course PAA "Friday afternoon", as pointed out throughout this thread MPL hasn't let anyone down, MPL over the past 7 years has not failed a single trial , K9 or Human , Cancer, Covid or MND. MPL has shown positive effect in every single trial carried out by independent third party Trial centres, Universities , Olivia Newton John Foundation, Walter and Eliza Hall Institute etc etc , including two of Australia's prominent MND specialists Rowe and Mathers and has undergone analysis with the Berry Institute and statistical comparisons utilising the Healey Platform comparisons.
Currently we can all be sure we don't know all of the facts ,,, this is not convivial for a Publicly Listed Entity which is based on transparency and public disclosure.
Many here know my view that communications have been lackluster at best but IMHO the poorest of any Biotech I have seen in 20 years,
Not only was Investor awareness poor (non existent) but market wide awareness was minimal , as we know from the droughts between information delivery that was then lightly peppered with information that needed to be unwound like a riddle from bland to boring Quarterlies including cryptic announcements which a significant amount of times resulted in SP decline..
IMHO this was a prominent factor in PAA being horrendously undervalued. (PAA was the only ASX listed Biotech to carry out a Successful Phase I Human Oncology Trial with a value under $100m.. ( Yes Buckland the Capsules were not Palatable or Tolerable but did however deliver a beneficial dose of MPL that showed reduction in tumour size)
All PAA Oncology Trial Patients had failed all standard of care.. but demonstrated Tumour Reduction.
So much so that even with a very poor tasting capsule the Company "Pharmaust" were approved to move forward to a Phase II Human Trial upon completion of a more palatable Tablet...
Sufficient data was obtained to permit proceeding to Phase II study, i.e. a safe and active dose. The study was also terminated to permit reformulation of study drug to a more palatable formulation.
ANZCTR Register
The Covid trial , well I don't have a week to write but 99% Viral Load reduction in 24 hours , Trialed at WEHI, Biolabs 360, then 9 months at the Lieden University , with a statement from one of if not the most prominent Professors Marc Pellergreni "The Result is Remarkable"
Professor Marc Pellegrini
The Centenary Institute is delighted to announce that Professor Marc Pellegrini will join the Centenary Institute as its new Executive Director. A physician, immunologist and internationally renowned research scientist, Professor Pellegrini has over 20 years of experience working on chronic infections.
Professor Pellegrini is currently Head of the Infectious Diseases and Immune Defence Division at the iconic WEHI in Melbourne, an institution with whom the Centenary has collaborated for many years.
This chart shows the actual viral load reduction , I can't take credit for this as I believe it was posted on a previous post.
Now full Blown Human infection with Covid was circa 35,000 parts per Million , above you can see that MPL reduced this to only 469 ppm with only 72 hours exposure to MPL,, ( Yes Buckland I know it was In Vitro , in the dish) But we were all told a Humanised Mouse Trial was scheduled, ( Later there were ASX announcements regarding Human Covid (Sars) Trials , in fact in multiple countries ,, even though at the time there was 29,000 live cases in Australia.
So a Human Tablet was required ,,, The K9 Tablet through the Beagle Trial showed that Beagles would take the newly formulated MPL Tablets from the clinicians hand from the ground ,,,repeatedly ,, The absolute significance of this was that Rats and Mice do not have the vomit gene (thus they can be easily poisoned as they can't regurgitate food or poison.
Dogs especially Beagles will not repeat consume anything that has made them sick in the past "sensory memory 20+ times stronger than Humans" This clearly showed that the tablets were tolerable and safe and that the Company could move forward toward Human Trials.
Now what also occurred was that standard MPL was altered / Reformulated it was micronised which increased it efficacy which now delivered a greater concentration of MPL so in effect a less amount had to be administered to deliver a beneficial dose, reducing Pill Burden for Patients. This was hugely significant moving forward as the Tablets could be manufactured "SMALL" so "EASY TO SWALLOW' and "LESS TO ADMINISTER" equals "LESS TO MANUFACTURE AND SHIP"
https://stocknessmonster.com/announcements/paa.asx-6A885431/
A Huge credit for all of the above to Dr. Richard MollardNow on the day of the ASX Announcement that Human Tablets Manufacturing had been completed the ASX Announcement resulted in SP decline?
There was a comment "Contained Contaminants" there should IMHO opinion been a full description of what contaminants can be classified as "Additional to necessity of the Tablets performance" in the MPL Human Tablet case "Contaminants" looked to be additional preservatives/ additional sucrose coatings/ additional stomach calming ingredients? I don't believe there was even an immediate reaction from the BOD to clarify this issue, But that's what this thread is about "No immediate Action to communicate with SH, Investors or the wider Media " Clarification was having to be sought directly from BOD members that many can show went unanswered.
Moving forward very little changed even during the MND Trial Patient recruitment , Thankfully Fight MND saw fit to trial the newly formulated Human MPL "Pharma-Pantel" against MND.
Lets fast forward ......,, first was the CEO search......... lets fast forward another 6 months ,,,, to when MT was appointed.
Communication was stepped up from an extremely low base , Professionalism was introduced and so was "Value" put on Brand Pharmaust.. no longer was it a stopped clock in the background but launched to an immediate (all be it virtual ) MT Boardroom with Pharmaust the Brand and Company name emblazoned on the back wall, Letting investors and SH know who MT was representing.. not difficult but hugely effective and an industry standard.
Then the previous PR and marketing company were replaced with NWR Communications and Matt Wright which saw the introduction of immediate Zoom / Webinars / Online Presentations and Updates and the delivery of the Investor Hub which proved highly beneficial for SH and Potential Investor communications , transparent , swift and effective,,, thanks NWR,, I believe PAA SH receive tremendous value from your Company and Team.
As its Saturday , I cant be arsed looking up a chart but lets just say the MC was lagging , MT moved the value needle with regular concise educational delivery of Data and updates on Trial and Trial Patient progress,,, first MC target knocked down $50m, $75m, $100m held for over 20 days ,,
MT and Blue Ocean then raised significant capital (Yes Buckland that caused a little dilution) SH Options previously sold to SH didn't reach the exercise price so were resold again at an additional couple of cents/ish...which brought in again a little extra cash but kept Options in safe hands.
The drop of the Phase I Data.. The after Hours delivery of data ,,,, well any long term Biotech investor would give you 90% odds anything after close is bad news ,,, but it was "Block buster" 12 from 12 , walking , talking , swallowing , QOL sustained Biomarkers confirming Disease Progression slowed significantly, giving life extension of an additional 12 to 54 months...
The next day IMHO was flat on news delivery but NWR and MT responded quickly and we all watched the SP rise to an all time High 53c.
Now we news that one patient has regrettably passed away , that Patient had a notoriously sinister form of MND
Bulbar onset motor neurone disease (MND), also known as progressive bulbar palsy (PBP), affects the muscles of the face, throat, and tongue. It's a rare disease that affects about 20% of people with MND. The first sign is usually slurred speech, caused by impaired tongue movement. Other signs include:
Now ,,, The Recruitment was not controlled by PAA , nor can they demand updates from Patients that are no longer on a Registered Clinical Trial.
end of...
rapidly moving forward as its now nightfall here in NZ and i need to light the fire brrrr.
CEO Resigns ,,, I'm not reducing the smack in the face but we have lost a CEO previously and IMHO MT is far more dynamic
MAY 2018
https://stocknessmonster.com/announcements/paa.asx-6A884712/
The Title of this ASX Announcement will clearly demonstrate PAA's level of Announcement from the past????
What does the future hold,,,,,
Well no matter what PAA require funding to progress from where we are $20m
FDA ODD Approval would certainly stimulate the SP (as long as the news is delivered to market clearly and effectively with direct reference to Value $$$$
We critically need to be part of the action with the Berry Institute utilising the Healey Platform.
Would I like to see MT back at the helm ,,, you bet I would ,, or Jeff or Elon but on the money PAA pay we are lucky to have MT..
I would also like to see a Commercial Valuation as PAA havent valued OUR IP or Commercial Advantage / Commercial Opportunity since 2017???
This would assist greatly to easily demonstrate to the wider market that PAA is chronically undervalued and a wise investment opportunity.
In closing I would like to thank those SH that I have had the privilege of speaking with personally for all the kind words and compassion shown during a difficult time for my family ..
in full disclosure , I have returned $337,000 from investing in PAA... I will continue to monitor the company progress and look for a significant entry point moving forward..
My only concern regarding ODD approval is the small cohort of Trial Patients of 12,,, if the FDA Consider MPL vs MND Mechanism of Action then it's 99% approved
I hope the above demonstrates that MPL /Pharmaust could be a serious investment opportunity that requires significant Management skills to be applied to bring forward to full commercialisation and a Revenue Position... these next few months are crucial..... forward momentum is crucial ,,,, Progress is crucial..
NZT
No hard feelings towards Buckland as I have agreed with his position on several occasions but mate "we get it" are Management up to the task?
up to individual SH opinions and standards
NZT
(20min delay)